Intrahepatic Cholestasis in Non-Alcoholic Fatty Liver Disease: Pathogenesis and Role of Ademetionine in Treatment by Ye. N. Shirokova

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease by Sun Xin, Zhang Yan, Xie Meilin

Subjects: “…non alcoholic fatty liver disease…”
Get full text

Role of Toll-Like Receptors and Their Downstream Molecules in the Development of Nonalcoholic Fatty Liver Disease by Kouichi Miura, Ekihiro Seki, Hirohide Ohnishi, David A. Brenner

“…Activation of innate immunity is associated with the development of liver disease, including non-alcoholic fatty liver disease (NAFLD). …”
Get full text

Response to: Comment on “Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease” by Stefano Bibbò, Maria Pina Dore, Giovanni Cammarota

Get full text

Associations between Extracellular Matrix Protein 1 Gene Polymorphism and Progression of Liver Disease by Xiuting He, Ting Liu, Rui Zhang, Xu Li

Get full text

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus by A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Rare forms of nonalcoholic fatty liver disease: hereditary lysosomal acid lipase deficiency by M. V. Mayevskaya, V. T. Ivashkin, M. S. Zharkova, T. P. Nekrasova, G. I. Ayusheva, R. V. Maslennikov

“…To acquaint general practitioners with a rarely diagnosed disease - the hereditary deficiency of lysosomal acid lipase (DLAL) which can develop under the «mask» non-alcoholic fatty liver disease (NAFLD). Summary. There are two forms of DLAL clinical manifestations: as fulminant lethal Wolman disease and slowly progressing cholesterol ethers storage disease (CESD). …”
Get full text

The Utility of Xenon-133 Liver Scan in the Diagnosis and Management of Nonalcoholic Fatty Liver Disease by Said A Al-Busafi, Peter Ghali, Philip Wong, Javier A Novales-Diaz, Marc Deschênes

“…Nonalcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver damage and is the most common cause of chronic liver diseases in Western countries. …”
Get full text

The Predictive Role of Parathyroid Hormone for Nonalcoholic Fatty Liver Disease following Bariatric Surgery by Tannaz Jamialahmadi, Mohsen Nematy, Mohammed Abdalla, Ali Jangjoo, Ladan Goshayeshi, Matthew Kroh, Seyed Adel Moallem, Mitra Abbasifard, Thozhukat Sathyapalan, Amirhossein Sahebkar

“…Morbid obesity is frequently complicated by chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and fibrosis. …”
Get full text

Increasing Whole Grain Intake as Part of Prevention and Treatment of Nonalcoholic Fatty Liver Disease by Alastair B. Ross, Jean-Philippe Godin, Kaori Minehira, John P. Kirwan

“…Due to their nutrient and phytochemical composition, switching from consuming mainly refined grains to whole grains should be considered as part of the nutritional guidelines for patients diagnosed with or at risk for fatty liver disease.…”
Get full text

Distribution of culture-positive microorganisms varies with severity of liver disease in patients hospitalized with SBP by Nadim Mahmud, Natalia Salinas Parra, Aaron L. Hecht, David E. Kaplan, Marina Serper

Get full text

The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review by Seyedeh Alia Moosavian, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar

“…Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease that can lead to end-stage liver disease needing a liver transplant. …”
Get full text

Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease by Wei Xuan, Dandan Song, Jianghua Hou, Xiuping Meng

“…Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease worldwide, but effective treatments are still lacking. …”
Get full text

Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease by Kadir Ozturk, Omer Kurt, Tolga Dogan, Alptug Ozen, Hakan Demirci, Fatih Yesildal, Murat Kantarcioglu, Turker Turker, Ahmet Kerem Guler, Yıldırım Karslioglu, Battal Altun, Ahmet Uygun, Sait Bagci

Get full text

Long-Term Effects of Metformin and Lifestyle Modification on Nonalcoholic Fatty Liver Disease Obese Adolescents by Lian Tock, Ana R. Dâmaso, Aline de Piano, June Carnier, Priscila L. Sanches, Henrique Manoel Lederman, Regina M. Y. Ernandes, Marco Túlio de Mello, Sérgio Tufik

Get full text

SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases by Minoru Fujimoto, Tetsuji Naka

“…Thus, SOCS1 and other SOCS proteins are potential targets for the therapy of human liver diseases.…”
Get full text

Elevated Bile Acids Induce Circadian Rhythm Sleep Disorders in Chronic Liver DiseasesSummary by Lan Zhou, Min Yan, Qin Luo, Wen Qiu, Yu-Ru Guo, Xiao-Qing Guo, Hong-Bin Yu, Jing-Ru Huo, Yan-Lin Feng, De-Ping Wang, Teng Sun, Kai-Fang Wang, Jian-Yun Shi, Xuan Shang, Mei-Na Wu, Lin Wang, Ji-Min Cao

Subjects: Get full text

Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity by Jae Hyun Bae, Young Min Cho

Get full text

Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society by V. T. Ivashkin, M. V. Mayevskaya, Ch. S. Pavlov, Yu. P. Sivolap, V. D. Lunkov, M. S. Zharkova, R. V. Maslennikov

“…To present clinical guidelines of the Russian Scientific Liver Society on diagnosis and treatment of alcoholic liver disease to general practitioners. Summary. Harmful alcohol intake is the burning issue for Russia. …”
Get full text

Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study by Steven Dooley, Juan Du, Xiaoping Tang, Lan Chen, Jinzhu Jia, Fujun Li, Yanyan Shi, Christoph Meyer, Zhongwei Zhu, Yanming Zhang, Roman Liebe, Keming Hu, Tingting Zhou, Huier Zhang, Hong-Lei Weng, Tong Huang

“…Eleven years of NAFLD are not sufficient to cause severe liver disease. Age and obesity are direct risk factors for NAFLD. …”
Get full text